162 results
6-K
EX-99
BLRX
Bioline Rx Ltd
6 May 24
Current report (foreign)
7:14am
other things, the potential benefits of APHEXDA, the execution of the launch of APHEXDA and the plans and objectives of management for future
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential benefits of APHEXDA
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
benefits of APHEXDA, the execution of the launch of APHEXDA and the plans and objectives of management for future operations and expectations
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily … employee benefits, including share option, restricted share unit, performance share unit and other equity-based compensation agreements under any
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon
424B5
83mvcb0a
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
9ei6x7mf
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
y3e 9ytmhhvwhtk
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
x3ea54r87nx ark
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
sbr14s2 1ena
16 Feb 24
Current report (foreign)
7:07am
F-3
tqt0 1de6wh8p3
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
klyee70
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
EX-99
pviyhv
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
i3mfi iowvt
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
zyfnhn
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
8oxfhod t8w4n8
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
EX-99
0eq5yl759ccxo 09
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
vmgiqzwql6 0lmm
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am